Compare PRPL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | NSRX |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 38.9M |
| IPO Year | 2015 | N/A |
| Metric | PRPL | NSRX |
|---|---|---|
| Price | $8.94 | $3.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $0.65 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 173.0K | 10.0K |
| Earning Date | 04-28-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $6.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $1.98 |
| 52 Week High | $8.50 | $9.99 |
| Indicator | PRPL | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 86.98 | 52.42 |
| Support Level | $0.54 | $2.83 |
| Resistance Level | N/A | $3.60 |
| Average True Range (ATR) | 0.62 | 0.18 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 98.58 | 79.64 |
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.